Floatz logo

Therapeutic Allogeneic Lymphocytes

Childhood Renal Cell Carcinoma

Fred Hutchinson Cancer CenterCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Childhood Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Children's Oncology Group
Phase 2B
DACTINOMYCIN
Children's Oncology Group
Phase 2B
Inno-206
Children's Oncology Group
Phase 2B
VINCRISTINE SULFATE
Children's Oncology Group
Phase 2B
Carboplatin
Children's Oncology Group
Phase 2B

View all 9 →

Same molecule, other indications

Therapeutic Allogeneic Lymphocytes is also rated in:

chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Relapsing Chronic Myelogenous LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →